Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 22, 2017

View Archived Issues

ICEC-0942 reduces tumor growth in preclinical models of breast cancer

Researchers develop a novel Crbn-mutant multiple myeloma mouse model

MAP1B gene found to be associated with periventricular nodular heterotopia

Phase II data presented for mAb hu3S193 in breast cancer patients

First patient treated in phase I study of Achillion's ACH-5228

European Commission approves Alecensa as first-line treatment in ALK-positive NSCLC

Frequency Therapeutics completes first-in-human study of drug candidate for hearing loss

Denali Therapeutics gives update on LRRK2 inhibitor programs

Arvinas selects second drug candidate

Jazz Pharmaceuticals submits NDA in U.S. for solriamfetol

First healthy subjects dosed in phase I trial of PRS-060

FDA issues complete response letter for Santen's NDA for intravitreal sirolimus

Spanish researchers patent RyR1 modulators

Novo Nordisk divulges new GDF-15 compounds

University of Patras presents geminin and Cdt1 interaction inhibitors

FDA grants priority review to Janssen's apalutamide NDA

An2H Discovery patents parkin modulators

Biohaven begins enrolling patients in phase II/III study of trigriluzole

Millendo Therapeutics acquires Alize Pharma

FDA approves ertugliflozin and combination therapies for type 2 diabetes

BAN-2401 does not meet criteria for success in phase II Alzheimer's study

BioLineRx begins phase III GENESIS trial

Ironwood Pharmaceuticals begins phase II study of IW-1701 in sickle cell disease

Celgene updates findings from phase III study of Revlimid plus rituximab in follicular lymphoma

Avelumab in combination with axitinib awarded FDA breakthrough therapy designation

FDA approves Giapreza to increase blood pressure in patients with septic or other distributive shock

Ionis Pharmaceuticals commences phase I trial of orally delivered antisense drug

FDA gives RMAT designation to Mesoblast's MPC therapy in heart failure

Roche to acquire Ignyta

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 15, 2026.
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...